Prescient Therapeutics: Professor H. Miles Prince
Professor H. Miles Prince AM, the Principal Investigator for the PTX-100 clinical trials, discusses the encouraging results of PTX-100 with its most recent Phase 1b trials as well as his vision for the future of this targeted therapy.
In this video, Professor Prince discusses:
- The Phase 1b study demonstrating response rates and remission durations that significantly surpass those of existing alternative therapies.
- Why PTX-100 aims to resolve issues that existing alternative therapies have been unable to address effectively.
- The next steps for PTX-100, including progressing toward a Phase 2 trial, supported by its Orphan Drug Designation.
Recorded on 17 October 2024 at 11:30am (AEDT)
Featured Speaker
Professor H. Miles Prince
Hematologist and Professor of Medicine
Professor H. Miles Prince is an internationally recognised Australian hematologist and a Professor at both Melbourne and Monash Universities. He is also the Professor/Director of Molecular Oncology and Cancer Immunology at the Epworth Centre, and a Hematologist at the Peter MacCallum Cancer Centre. As a global expert in T-cell lymphomas, Professor Miles acts as the Principal Investigator for the PTX-100 clinical trials. He holds major Australian, American and European research grants and has published over 450 journal articles. In 2014 he was awarded a Member of the Order of Australia (general division) for significant services to blood cancer research, patient care and philanthropy leadership.
